The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

OBJECTIVE: A 12-week study assessed the efficacy and safety of a new oral antidiabetic agent, imeglimin, as add-on therapy in type 2 diabetes patients inadequately controlled with metformin alone. RESEARCH DESIGN AND METHODS: A total of 156 patients were randomized 1:1 to receive imeglimin (1,500 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Fouqueray, Pascale, Pirags, Valdis, Inzucchi, Silvio E., Bailey, Clifford J., Schernthaner, Guntram, Diamant, Michaela, Lebovitz, Harold E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579350/
https://www.ncbi.nlm.nih.gov/pubmed/23160726
http://dx.doi.org/10.2337/dc12-0453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579350/
https://www.ncbi.nlm.nih.gov/pubmed/23160726
http://dx.doi.org/10.2337/dc12-0453

Ejemplares similares